Innovative Genomic Profiling in HR+/HER2- Metastatic Breast Cancer

In this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and learn about the advantages of liquid biopsy testing.

Genomic Testing in the Clinic

Join Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies.